Newer drug treatments: Their effects on fracture prevention

P Geusens, D Reid

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Drug treatment of osteoporosis is based on the knowledge of mechanisms of bone turnover and the manipulation of the cellular components of bone turnover in terms of recruitment, activation and apoptosis of the cells involved. Based on their mechanisms of action, drugs used in the treatment of osteoporosis can be divided into those that inhibit bone turnover (bisphosphonates, SERMs, calcitonin), those that stimulate bone turnover (parathyroid hormone), and those with mixed effects (strontium ranelate). In this chapter we discuss the anti-fracture effects of some newer drugs together with innovative aspects of intake (monthly oral intake for ibandronate) or mechanisms of action (parathyroid hormone and strontium ranelate). Some new drugs that are being studied for their potential anti-fracture effects are listed.

Original languageEnglish
Pages (from-to)983-989
Number of pages7
JournalBest Practice & Research Clinical Obstetrics & Gynaecology
Volume19
DOIs
Publication statusPublished - 2005

Keywords

  • strontium ranelate
  • ibandronate
  • zoledronate
  • parathyroid hormone
  • RANKL
  • calcitonin
  • BONE-MINERAL DENSITY
  • POSTMENOPAUSAL WOMEN
  • OSTEOPOROSIS
  • RISK

Cite this

Newer drug treatments: Their effects on fracture prevention. / Geusens, P ; Reid, D .

In: Best Practice & Research Clinical Obstetrics & Gynaecology, Vol. 19, 2005, p. 983-989.

Research output: Contribution to journalArticle

@article{16d008a986924a9592178be96ed57cb6,
title = "Newer drug treatments: Their effects on fracture prevention",
abstract = "Drug treatment of osteoporosis is based on the knowledge of mechanisms of bone turnover and the manipulation of the cellular components of bone turnover in terms of recruitment, activation and apoptosis of the cells involved. Based on their mechanisms of action, drugs used in the treatment of osteoporosis can be divided into those that inhibit bone turnover (bisphosphonates, SERMs, calcitonin), those that stimulate bone turnover (parathyroid hormone), and those with mixed effects (strontium ranelate). In this chapter we discuss the anti-fracture effects of some newer drugs together with innovative aspects of intake (monthly oral intake for ibandronate) or mechanisms of action (parathyroid hormone and strontium ranelate). Some new drugs that are being studied for their potential anti-fracture effects are listed.",
keywords = "strontium ranelate, ibandronate, zoledronate, parathyroid hormone, RANKL, calcitonin, BONE-MINERAL DENSITY, POSTMENOPAUSAL WOMEN, OSTEOPOROSIS, RISK",
author = "P Geusens and D Reid",
year = "2005",
doi = "10.1016/j.berh.2005.07.003",
language = "English",
volume = "19",
pages = "983--989",
journal = "Best Practice & Research Clinical Obstetrics & Gynaecology",
issn = "1521-6934",
publisher = "Bailliere Tindall Ltd",

}

TY - JOUR

T1 - Newer drug treatments: Their effects on fracture prevention

AU - Geusens, P

AU - Reid, D

PY - 2005

Y1 - 2005

N2 - Drug treatment of osteoporosis is based on the knowledge of mechanisms of bone turnover and the manipulation of the cellular components of bone turnover in terms of recruitment, activation and apoptosis of the cells involved. Based on their mechanisms of action, drugs used in the treatment of osteoporosis can be divided into those that inhibit bone turnover (bisphosphonates, SERMs, calcitonin), those that stimulate bone turnover (parathyroid hormone), and those with mixed effects (strontium ranelate). In this chapter we discuss the anti-fracture effects of some newer drugs together with innovative aspects of intake (monthly oral intake for ibandronate) or mechanisms of action (parathyroid hormone and strontium ranelate). Some new drugs that are being studied for their potential anti-fracture effects are listed.

AB - Drug treatment of osteoporosis is based on the knowledge of mechanisms of bone turnover and the manipulation of the cellular components of bone turnover in terms of recruitment, activation and apoptosis of the cells involved. Based on their mechanisms of action, drugs used in the treatment of osteoporosis can be divided into those that inhibit bone turnover (bisphosphonates, SERMs, calcitonin), those that stimulate bone turnover (parathyroid hormone), and those with mixed effects (strontium ranelate). In this chapter we discuss the anti-fracture effects of some newer drugs together with innovative aspects of intake (monthly oral intake for ibandronate) or mechanisms of action (parathyroid hormone and strontium ranelate). Some new drugs that are being studied for their potential anti-fracture effects are listed.

KW - strontium ranelate

KW - ibandronate

KW - zoledronate

KW - parathyroid hormone

KW - RANKL

KW - calcitonin

KW - BONE-MINERAL DENSITY

KW - POSTMENOPAUSAL WOMEN

KW - OSTEOPOROSIS

KW - RISK

U2 - 10.1016/j.berh.2005.07.003

DO - 10.1016/j.berh.2005.07.003

M3 - Article

VL - 19

SP - 983

EP - 989

JO - Best Practice & Research Clinical Obstetrics & Gynaecology

JF - Best Practice & Research Clinical Obstetrics & Gynaecology

SN - 1521-6934

ER -